Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage
Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...
Company
CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment
Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...
Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...
Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G
Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...
CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome
China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...
Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC
China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...
Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development
Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series...
Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA
China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...
Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion
US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...
Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...
Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy
Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...
Eversana Forms Strategic Alliance with China Resource Pharmaceutical for Healthcare Expansion
US-based commercial services provider Eversana has announced a strategic alliance with China Resource Pharmaceutical Commercial...
Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs
Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...
Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...
Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection
US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed...
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...